375.84
0.92 (0.25%)
| Previous Close | 374.91 |
| Volume | 65,663 |
| Price / Earnings (Forward) | 40.88 |
| Price / Sales | 3.90 |
| Price / Book | 1.40 |
| 52 Weeks Range |
| Profit Margin | -85.16% |
| Operating Margin (TTM) | 9.72% |
| Diluted EPS (TTM) | -76.53 |
| Quarterly Revenue Growth (YOY) | -4.20% |
| Quarterly Earnings Growth (YOY) | -83.30% |
| Total Debt/Equity (MRQ) | 20.50% |
| Current Ratio (MRQ) | 5.99 |
| Operating Cash Flow (TTM) | 515.30 M |
| Levered Free Cash Flow (TTM) | 250.23 M |
| Return on Assets (TTM) | 1.55% |
| Return on Equity (TTM) | -27.52% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Bio-Rad Laboratories, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | -0.5 |
| Price Volatility | -5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Relative Valuation | NA |
| Financial Health | 2.2 |
| Macro Environment | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -0.57 |
Select this tab to load the latest available analysis.
|
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 16.14% |
| % Held by Institutions | 93.04% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| First Pacific Advisors, Lp | 30 Jun 2026 | 401,861 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| DIVINCENZO JONATHAN P. | - | 369.95 | -951 | -351,822 |
| Aggregate Net Quantity | -951 | |||
| Aggregate Net Value ($) | -351,822 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 369.95 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| DIVINCENZO JONATHAN P. | Officer | 24 Oct 2026 | Disposed (-) | 951 | 369.95 | 351,822 |
| DIVINCENZO JONATHAN P. | Officer | 24 Oct 2026 | Option execute | 1,869 | - | - |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |